Release Date: 18-Dec-2025
Orphan drugs, also known as rare drugs, have steadily emerged as an innovative segment in the pharmaceutical industry of the US. These drugs target diseases that affect fewer than 200,000 people across the US, and hence less profitable using the conventional approach. Despite this, the use of tax credits and grants by the US government through the Orphan Drug Act of 1983 to encourage the development of these drugs has led to the rapid growth of the development of these drugs. This has resulted in the emergence of innovative drugs that have transformed the face of rare diseases.
Download Report: https://www.kuickresearch.com/report-fda-orphan-drug-database
One such dramatic example of innovation is Luxturna (voretigene neparvovec), a gene therapy that received approval from the FDA in 2017 for the treatment of an inherited retinal disease caused by mutations in the RPE65 gene. This leads to vision impairment, finally resulting in blindness. Luxturna is the first gene therapy developed by the FDA specifically for the treatment of an inherited genetic disorder by introducing a working version of the gene itself into the retina. It is not only a revolutionary advancement in the realm of ophthalmology but also exemplifies the capability of gene therapies for curing rare genetic disorders by offering long-lasting solutions. Therefore, Luxturna is a milestone achievement in genetic treatments.
Another exemplary breakthrough orphan drug is Zolgensma (onasemnogene abeparvovec-xioi), which is a gene therapy approved for the management of Spinal Muscular Atrophy (SMA), a profoundly damaging genetic disorder that causes muscle weakness and, in severe cases, infant mortality. Zolgensma is the first single-stage gene therapy, approved by the FDA in 2019 to halt or reverse the course of SMA when administered within the first few months of life. It is historic not only in the management of SMA, where transplantation of motor neurons has been of limited benefit, but also in the field of gene therapy. Gene therapy is a viable means of treating rare diseases without any approved therapeutic modalities.
Emflaza (deflazacort), a corticosteroid employed in the treatment of Duchenne muscular dystrophy, is another instance of how an orphan drug leads the way in innovation. Approved by the FDA in the year 2017, Emflaza is an alternative to the corticosteroids that until then were the only major hope for the effective treatment of Duchenne muscular dystrophy. This is particularly significant since an alternative is now available for all those patients who were not responding well to the earlier treatments. Alongside, the FDA approval of Emflaza has opened the doors for new, less toxic treatments of Duchenne muscular dystrophy, which is primarily related to the strength and function of the muscular tissues.
These are just a few instances of these breakthroughs in the pharmaceutical industry. As the scientific community is increasingly concentrating its efforts on discovering a cure for rare diseases, advances such as CRISPR Gene Editing technology, RNA therapy, and Personalized Medicine are pushing forward a new era of orphan drugs and their innovative uses in contemporary society. In doing so, orphan drugs are changing not only lives within the area of healthcare but are also shaping the pharmaceutical market itself through their groundbreaking applications.
The emergence of orphan drugs has triggered collaborations between pharmaceutical giants, academia, and biotech firms, thereby giving rise to a vibrant setting for innovative advancements in the field of healthcare. The collaborations currently in progress are expected to usher in a new wave of innovative therapies and methods, which will pave the way for the arrival of therapies that could be more widely beneficient. The long-term implications of orphan drug development reach beyond the horizon of rare disease treatment and the future of the field of medicine itself.